Tuesday, 29 June 2010
Leading-edge Medical Device investment demonstrates Ireland’s reputation as a key Research and Development Location.
Dublin, Minister for Enterprise, Trade and Innovation, Batt O’Keffe TD, today (18th June 2010) welcomed the announcement by Biotrin, a leading developer and manufacturer of diagnostic platform technology, of an investment in a new Research and Development (R&D) project in Dublin with the creation of 40 new high end jobs. The expansion is supported by the Irish Government with the aid of IDA Ireland. Biotrin is owned by an Italian Diagnostic company, Diasorin S.p.A.
The new project will involve the development of automated molecular diagnostics platform technology and assay reagents for the detection of target DNA and RNA in infectious diseases. It will be based on a new molecular diagnostics technology called loop-mediated isothermal amplification (LAMP). This venture establishes the Dublin site as Diasorin’s Corporate headquarters for Molecular Diagnostics R&D and will bring the total job numbers at the facility to over 100.
Announcing the jobs today, Minister O'Keeffe said the investment 'demonstrates Ireland's attractiveness for leading-edge medical device investments. The development of new diagnostic technologies is the type of high-end activity the Government is eager to support as part of our efforts to build the "smart" economy and innovation island. Ireland.has a strong cluster of firms in the life science sector with eight of the top 10 pharmaceutical and 15 of the top 20 medical devices companies based here. The 40 new jobs will add to our reputation as a global leader for life science firms,' said Minister O'Keeffe.
Dr. Carlo Rosa, CEO Diasorin stated that ‘This project is a key element of DiaSorin’s, Biotrin’s parent company, RD&I strategy underpinning developments in automation and molecular diagnostics. The choice to locate this operation in Ireland was based on its strong reputation as an RD&I location and on the success of Biotrin’s existing operation here. Automated molecular diagnostics is a key part of DiaSorin’s corporate strategy and we look forward to further developing our operations in Ireland as a vital part of this strategy.’
IDA CEO, Barry O’Leary said, ‘Biotrin’s investment adds to Ireland’s reputation as a global hub for the Life Sciences sector. R&D expansions such as this embed existing operations and pave the way for future investment and job creation. On behalf of IDA I look forward to working closely with Biotrin as it continues to grow and develop its operations in Ireland.’